Management of Venous Sinus Thrombosis.

Nicholas Sader, Madeleine de Lotbinière-Bassett, Michael K Tso, Mark Hamilton

Journal: Neurosurgery clinics of North America 2018;29(4):585-594

PMID: 30223971

Full Text on Elsevier Science View on PubMed

Abstract

Cerebral venous sinus thrombosis (CVST) is a rare subtype of cerebrovascular disease representing 0.5% of strokes. The signs and symptoms of CVST are often nonspecific, and variable in duration, with the common results being delayed diagnosis and treatment. Increased awareness in the medical community and advancements in imaging modalities have produced faster diagnosis with improved patient outcomes. The preferred initial treatment is with a low molecular weight heparin. After the acute stage of CVST, treatment with a vitamin K antagonist (oral anticoagulant therapy) is recommended. Current evidence suggests that in the future, factor Xa inhibitor drugs may be used for long-term therapy.

Address: Division of Neurosurgery, Department of Clinical Neurosciences, University of Calgary, Foothills Hospital, 12th Floor, 1403 - 29th Street Northwest, Calgary, Alberta T2N 2T9, Canada.; Adult Hydrocephalus Program, Division of Neurosurgery, Department of Clinical Neurosciences, University of Calgary, Adult Hydrocephalus Clinical Research Network, Foothills Hospital, 12th Floor, 1403 - 29th Street Northwest, Calgary, Alberta T2N 2T9, Canada. Electronic address: [email protected].

DOI: 10.1016/j.nec.2018.06.011

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/30223971

Subscription / membership required

Full Text Sources:

MeSH Terms: Anticoagulants, Humans, Risk Factors, Sinus Thrombosis, Intracranial, Treatment Outcome